AVAILABLENot Applicable

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

Plain-language summary

Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion: N/A Key Exclusion: N/A

NCT IDNCT04710056

SponsorRegeneron Pharmaceuticals

Sponsor typeINDUSTRY

Study typeEXPANDED_ACCESS

Requests for Expanded Access must be initiated by a treating physician. Physicians should contact